|
1
|
Walther MM, Herring J, Enquist E, Keiser
HR and Linehan WM: von Recklinghausen's disease and
pheochromocytomas. J Urol. 162:1582–1586. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edström Elder E, Skog AL Hjelm, Höög A and
Hamberger B: The management of benign and malignant
pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol.
29:278–283. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schürmeyer T, Dralle H, Schuppert F and
von zur Mühlen A: Preoperative diagnosis of suspected
pheochromocytoma - retrospective assessment of diagnostic criteria.
Acta Med Austriaca. 15:106–108. 1988.(In German). PubMed/NCBI
|
|
4
|
Roman-Gonzalez A and Jimenez C: Malignant
pheochromocytoma-paraganglioma: Pathogenesis, TNM staging, and
current clinical trials. Curr Opin Endocrinol Diabetes Obes.
24:174–183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kopf D, Goretzki PE and Lehnert H:
Clinical management of malignant adrenal tumors. J Cancer Res Clin
Oncol. 127:143–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vousden KH and Lu X: Live or let die: The
cell's response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oren M: Decision making by p53: Life,
death and cancer. Cell Death Differ. 10:431–442. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin SR, Lee YJ and Tsai JH: Mutations of
the p53 gene in human functional adrenal neoplasms. J Clin
Endocrinol Metab. 78:483–491. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshimoto T, Naruse M, Zeng Z, Nishikawa
T, Kasajima T, Toma H, Yamamori S, Matsumoto H, Tanabe A, Naruse K,
et al: The relatively high frequency of p53 gene mutations in
multiple and malignant phaeochromocytomas. J Endocrinol.
159:247–255. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang V, Qin Y, Wang J, Wang X, Place RF,
Lin G, Lue TF and Li LC: RNAa is conserved in mammalian cells. PLoS
One. 5:e88482010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Milner J, Medcalf EA and Cook AC: Tumor
suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol
Cell Biol. 11:12–19. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamaru R and Ishioka C: Understanding the function-structure
and function-mutation relationships of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:pp. 8424–8429. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schlomm T, Iwers L, Kirstein P, Jessen B,
Köllermann J, Minner S, Passow-Drolet A, Mirlacher M,
Milde-Langosch K, Graefen M, et al: Clinical significance of p53
alterations in surgically treated prostate cancers. Mod Pathol.
21:1371–1378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ge Q, Wang C, Ruan Y, Chen Z, Liu J and Ye
Z: Overexpression of p53 activated by small activating RNA
suppresses the growth of human prostate cancer cells. Onco Targets
Ther. 9:231–241. 2016.PubMed/NCBI
|
|
18
|
Wang C, Ge Q, Zhang Q, Chen Z, Hu J, Li F
and Ye Z: Targeted p53 activation by saRNA suppresses human bladder
cancer cells growth and metastasis. J Exp Clin Cancer Res.
35:532016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brugarolas J, Chandrasekaran C, Gordon JI,
Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest
compromised by p21 deficiency. Nature. 377:552–557. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Waldman T, Kinzler KW and Vogelstein B:
p21 is necessary for the p53-mediated G1 arrest in human cancer
cells. Cancer Res. 55:5187–5190. 1995.PubMed/NCBI
|
|
21
|
Del Sal G, Murphy M, Ruaro E, Lazarevic D,
Levine AJ and Schneider C: Cyclin D1 and p21/waf1 are both involved
in p53 growth suppression. Oncogene. 12:177–185. 1996.PubMed/NCBI
|
|
22
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Waga S, Hannon GJ, Beach D and Stillman B:
The p21 inhibitor of cyclin-dependent kinases controls DNA
replication by interaction with PCNA. Nature. 369:574–578. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Plati J, Bucur O and Khosravi-Far R:
Dysregulation of apoptotic signaling in cancer: Molecular
mechanisms and therapeutic opportunities. J Cell Biochem.
104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fulda S: Tumor resistance to apoptosis.
Int J Cancer. 124:511–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Groeger AM, Esposito V, De Luca A,
Cassandro R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC,
Baldi A, et al: Prognostic value of immunohistochemical expression
of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung
cancers. Histopathology. 44:54–63. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li LC, Okino ST, Zhao H, Pookot D, Place
RF, Urakami S, Enokida H and Dahiya R: Small dsRNAs induce
transcriptional activation in human cells. Proc Natl Acad Sci USA.
103:pp. 17337–17342. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Place RF, Noonan EJ, Földes-Papp Z and Li
LC: Defining features and exploring chemical modifications to
manipulate RNAa activity. Curr Pharm Biotechnol. 11:518–526. 2010.
View Article : Google Scholar : PubMed/NCBI
|
